CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Tocilizumab InjectionWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.08

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Multicenter Study on the Efficacy and Tolerability of Tocilizumab in the Treatment of Patients With COVID-19 Pneumonia

This study project includes a single-arm phase 2 study and a parallel observational cohort study, enrolling patients with COVID-19 pneumonia.

NCT04317092 COVID-19 Pneumonia Drug: Tocilizumab Injection
MeSH:Pneumonia
HPO:Pneumonia

Primary Outcomes

Description: 1-month mortality is defined as the ratio of patients who will alive after 1month from study start out of those registered at baseline

Measure: One-month mortality rate

Time: up to 1 month

Secondary Outcomes

Description: IL-6 levels will be assessed using commercial ELISA method.

Measure: Interleukin-6 level

Time: baseline, during treatment (cycle 1 and 2 every 12 hours) up to 1 month

Description: Lymphocyte count assessed by routinely used determination of blood count

Measure: Lymphocyte count

Time: baseline, during treatment (cycle 1 and 2 every 12 hours) up to 1 month

Description: CRP is assessed by routinely used determination of CRP

Measure: CRP (C-reactive protein) level

Time: baseline, during treatment (cycle 1 and 2 every 12 hours) up to 1 month

Description: calculated from arterial blood gas analyses (values from 300 to 100)

Measure: PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)

Time: baseline, during treatment (cycle 1 and 2 every 12 hours) up to 1 month

Description: It evaluates 6 variables, each representing an organ system (one for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems), and scored from 0 (normal) to 4 (high degree of dysfunction/failure). Thus, the maximum score may range from 0 to 24.

Measure: Change of the SOFA (Sequential Organ Failure Assessment)

Time: baseline, during treatment (cycle 1 and 2 every 12 hours) up to 1 month

Description: graded according to CTCAE citeria (v5.0)

Measure: Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0

Time: during treatment and up to 30 days after the last treatment dose

Description: Thoracic CT scan or Chest XR

Measure: Radiological response

Time: at baseline (optional), after seven days and if clinically indicated (up to 1 month)

Description: Days of hospitalization

Measure: Duration of hospitalization

Time: from baseline up to patient's discharge (up to 1 month)

Description: time to invasive mechanical ventilation (if not previously initiated) calculated from baseline to intubation

Measure: Remission of respiratory symptoms

Time: up to 1 month

Description: time to definitive extubation calculated from intubation (any time occurred) to extubation in days

Measure: Remission of respiratory symptoms

Time: up to 1 month

Description: time to independence from non-invasive mechanical ventilation calculated in days

Measure: Remission of respiratory symptoms

Time: up to 1 month

Description: time to independence from oxygen therapy in days

Measure: Remission of respiratory symptoms

Time: up to 1 month

Related HPO nodes (Using clinical trials)

HP:0002090: Pneumonia
Genes 208
TIMM8A DNAH9 GAS8 DNAH11 TNFRSF11A TBC1D24 SPAG1 MS4A1 GAS2L2 CCDC151 NIPBL BTK LIG4 NFKB2 TCIRG1 IGLL1 RNF168 STAT3 TAF1 RSPH4A CFTR NME8 DNAAF4 LEP CCDC65 NADK2 CD55 COL11A2 NHLRC1 PEPD CFAP300 LTBP3 WAS DNAI1 TBCD IL2RG GFI1 NBN RSPH1 CCDC39 PMM2 ICOS TNFSF12 IFNGR1 CARD11 SFTPC DNAL1 OFD1 ZMYND10 IL21R FMO3 SLC35A1 PLOD1 ORC6 RAG2 CACNA1C GAS8 RYR1 CFAP298 GNPTAB TNFRSF13B KDM6A PANK2 RANBP2 CYBA USB1 UBB DOCK8 ADA DNAAF2 KMT2D SAMD9 MUC5B IL7R DNAAF1 ICOS RAG2 CARD11 PTPRC ALMS1 NOTCH3 NSMCE3 DNAI1 TNFRSF13C GRHL3 EGFR IL2RG DNAAF6 PNP DNAH5 SETBP1 CR2 CD3E ADA MASP2 SFTPA2 ACTA1 RAC1 TTC25 FCGR2A ZAP70 SPEF2 IGHM DNAAF5 NBN CD247 DDR2 CD19 ACADVL KIAA0586 TK2 BLNK ARMC4 SGCG RAG1 CXCR4 NCF1 SRP54 FOXP3 IRF8 CFAP221 RNU4ATAC KCNJ6 LRBA CD3D P4HTM SELENON CCDC114 TNFRSF13B PLG DCLRE1C SLC25A24 DCLRE1C ICOS IL7R FOXJ1 JAK3 IL2RG CASP8 RAG1 OSTM1 CFAP410 CCNO NCF2 UNC119 TNFRSF13C JAK3 RNF125 STK36 POLA1 CD19 CR2 DNAH1 RSPH3 RSPH9 CYBB DRC1 DCLRE1C CCDC103 DNAAF3 LRRC56 PIGN LRRC6 SP110 PRKCD ACP5 CCDC40 SLC35C1 BTK MTHFD1 PGM3 RAG1 TERT CHD7 CFB TGFB1 RNU4ATAC SMARCD2 NKX2-1 OFD1 ZBTB24 BTK DNAI2 WDR19 ZAP70 CD79B CD81 COL11A2 NFIX RAG2 ELANE AFF4 NFKB1 IL2RG TNFRSF13C TNFSF12 CCDC114 ADA GBA DNAJB13 RPGR CSPP1 RMRP EPM2A DNMT3B NFKB2 MCIDAS HYDIN
Protein Mutations 6
A2063G G551D K55R L460D R287Q S1009A
SNP 0